Capstone Therapeutics Corp
OTC:CAPS
Capstone Therapeutics Corp
Non-Reccuring Items
Capstone Therapeutics Corp
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Capstone Therapeutics Corp
OTC:CAPS
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Capstone Therapeutics Corp
Glance View
Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.
